AIM To observe the clinical effects of esmolol and amiodarone in the treatment of rapid atrial fibrillation (AF) in patients with midrange ejection fraction heart failure (HFmrEF).
METHODS Ninety cases of rapid AF with HFmrEF in our hospital from January 2017 to December 2019 were randomly divided into two groups of 45 patients. The control group was given intravenous amiodarone and the study group was administered intravenous esmolol. The ventricular rate, efficacy and blood B-type natriuretic peptide (BNP) were compared between the two groups.
RESULTS After treatment, the decrease of ventricular rate in the study group was statistically significant compared with that in the control group (P < 0.05, P < 0.01), especially during the treatment of (5-15) minutes (P < 0.01). There was no statistical difference in the total effective rate between the two groups, but the difference was statistically significant during the treatment of (5-30) minutes (P < 0.05, P < 0.01), especially during the treatment of (5-15) minutes (P < 0.01). The average onset time of control group and study group was (32±6) min and (10±4) min. After treatment, BNP in the study group decreased significantly (P < 0.05).
CONCLUSION Intravenous esmolol and amiodarone are both safe and effective in the treatment of rapid AF with HFmrEF, but esmolol is faster and more effective.
DownLoad: